Tristel (LON:TSTL), which makes infection control and hygiene products, reported a strong first half as it continues to roll out internationally and announced 95% increase in the interim dividend.
Pre-tax profit before share based payments for the six months to end December was up 36% to £1.5mln (2014: £1.1m) on revenues, which were up 8% to £8mln.
Overseas sales rose 20% to £2.9mln compared to £2.4mln in 2014., and represented 36% of total sales.
Paul Swinney, chief executive, told investors: "We are pleased to report strong half-on-half profits growth, which has translated into an increase in cash and a substantial increase in the interim dividend.
"Our international expansion continues with many regulatory approvals awaited, not only in healthcare markets in which we already sell, but also in countries in which we have no presence. This includes the United States."
He added that two products have been selected for its approach to the US market, and the group is talking to the FDA in preparation for a full regulatory approval submission during 2016.
The board declared an interim dividend of 1.14 pence, payable on April 1 this year, against a payment of 0.585p for 2014.
Shares added 1.37% to stand at 147.5p.